Compare Motorola Solutions Inc (MSI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Neurocrine Biosciences Inc — how do they compare? Motorola Solutions Inc trades at $446.82 (market cap $74.20B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Motorola Solutions Inc is far larger — about 5.1× Neurocrine Biosciences Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MSI | NBIX | |
|---|---|---|
Market Cap | $74.20B | $14.60B |
Volume | 720,826 | 1,075,694 |
Sector | Technology | Health |
52-Week High | $491.24 | $185.50 |
52-Week Low | $363.83 | $123.10 |
Typical Hold Time | 100 Days | 23 Days |
Enterprise Value | $83.10B | $14.61B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $447.12, down 2.02% today, amid a bearish technical signal. The company maintains strong fundamentals with Q2 2026 EPS of $4.41 beating expectations and record backlog of $15.6 billion. Recent acquisitions including D-Fend Solutions for $1.5 billion expand its counter-drone security capabilities, while new contracts with Louisiana and the US Navy demonstrate ongoing demand.
MSI presents a compelling growth story with robust earnings momentum and strategic expansion, though elevated valuation ratios and significant capital expenditures pose risks. Analyst consensus remains bullish with a $525.86 price target, representing 17.6% upside potential from current levels.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
